<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374503</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-0651-1.1/11</org_study_id>
    <nct_id>NCT01374503</nct_id>
  </id_info>
  <brief_title>First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4</brief_title>
  <official_title>A Phase I, Single-centre, Randomised, Single-blinded, Placebo-controlled Single Ascending Dose Study, Followed by an Open-label Extension, Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of ALX-0651, Administered Intravenously to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor&#xD;
      ALX-0651 is safe and effective after single or multiple intravenous administrations to&#xD;
      healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Proof of principle established with completed SAD part&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>until 1 month after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration (Cmax) of ALX-0651</measure>
    <time_frame>from predose until 48 hours after study drug administration</time_frame>
    <description>Plasma concentration of ALX-0651 will be determined at different timepoints between predose and 48 hours after the last study drug administration. The maximum plasma concentration (Cmax) of ALX-0651 will be derived from the resulting plasma concentration versus time plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34 positive cell count in blood</measure>
    <time_frame>from predose until 14 days after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ALX-0651</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0651</intervention_name>
    <description>single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg</description>
    <arm_group_label>ALX-0651</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single or multiple i.v. administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers, aged &gt;= 18 and &lt;= 55 at screening.&#xD;
&#xD;
          -  Willing to consent to using an effective contraceptive method for at least 3 months&#xD;
             after test substance administration.&#xD;
&#xD;
          -  Non-smokers, or ex-smokers abstinent from tobacco for at least 1 year.&#xD;
&#xD;
          -  Body mass index (BMI): 19 - 29 kg/m2 (extremes included).&#xD;
&#xD;
          -  Haematology and chemistry parameters within normal range or showing no clinically&#xD;
             relevant deviations, as judged by the Medical Investigator. For haematology,&#xD;
             haemoglobin and white blood cell (WBC) count must be within normal limits. For&#xD;
             chemistry, calcium, alkaline phosphatase (ALP), (alanine aminotransferase (ALT),&#xD;
             aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and lactate&#xD;
             dehydrogenase (LDH) must be within normal limits.&#xD;
&#xD;
          -  Normal electrocardiogram, showing no clinically relevant deviations, as judged by the&#xD;
             Investigator. QTc &lt;= 450 ms.&#xD;
&#xD;
          -  No history or presence of diseases of the kidneys, heart, lungs, liver,&#xD;
             gastrointestinal tract or endocrine organs, or other conditions known to interfere&#xD;
             with the absorption, distribution, metabolism or excretion of drugs.&#xD;
&#xD;
          -  No history of clinically relevant allergies.&#xD;
&#xD;
          -  Obtained, signed and dated informed consent.&#xD;
&#xD;
          -  Ability and willingness to comply with protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intake of any prescribed systemic or topical medication within 14 days prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Intake of vitamin A derivates or retinoids within 30 days prior to the start of drug&#xD;
             administration.&#xD;
&#xD;
          -  History of thrombosis.&#xD;
&#xD;
          -  Chronic infection or acute significant infection or fever within the last 5 weeks&#xD;
             prior to the start of test substance administration.&#xD;
&#xD;
          -  Subjects with any abnormality of the spleen (confirmed by echography) or history of&#xD;
             splenic disease, or subjects that underwent splenectomy in the past.&#xD;
&#xD;
          -  Blood donation (&gt;500 ml) or a comparable blood loss within three months prior to the&#xD;
             start of drug administration.&#xD;
&#xD;
          -  Subjects who, in the investigator's opinion, may not be capable of following the study&#xD;
             schedule for any reason, with special emphasis on eligibility for the aphaeresis&#xD;
             procedure.&#xD;
&#xD;
          -  Participation in an investigational drug study within 60 days prior to drug&#xD;
             administration, or within less than 6 times the terminal elimination half-life of the&#xD;
             test substance used in the respective trial (whichever is longer).&#xD;
&#xD;
          -  Malignancy, or prior malignancy, with a disease-free interval of &lt; 5 years after&#xD;
             diagnosis and intervention, except curative treatment for non-melanoma skin cancer or&#xD;
             resected carcinoma in situ.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josefin-Beate Holz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

